Loading...
•
Dec 31, 2022
IRadimed Q4 2022 Earnings Report
IRadimed reported record revenue for the sixth consecutive quarter and approved a special cash dividend.
Key Takeaways
IRadimed Corporation announced its Q4 and full year 2022 financial results, reporting a revenue of $14.9 million for the quarter and $53.3 million for the year. The Board of Directors approved a special cash dividend of $1.05 per share. The company ended the year with $57.9 million in cash and cash equivalents and no debt.
Reported fourth quarter revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted EPS of $0.32.
Reported full-year revenue of $53.3 million, GAAP diluted EPS of $1.02 and non-GAAP diluted EPS of $1.10.
Board of Directors approved a special cash dividend of $1.05 per share.
Ended the year with $57.9 million in cash and cash equivalents and no debt.
Forward Guidance
For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34. For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.
Positive Outlook
- Revenue of $61 million to $63 million
- GAAP diluted earnings per share of $1.10 to $1.20
- Non-GAAP diluted earnings per share of $1.23 to $1.34
- First quarter revenue of $14.6 million to $14.9 million
- First quarter GAAP diluted earnings per share of $0.23 to $0.25
Challenges Ahead
- Stock-based compensation expense impacts non-GAAP diluted earnings per share guidance
- Potential disruptions in our limited supply chain for our products
- The Company's ability to receive FDA 510(k) clearance for new products and product candidates
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...